Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 913 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active comparator control Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 22, 2026, 2:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Motor Imagery Exercise and Tongue Strength

NCT03423095
View directory record Official record
Conditions
Dysphagia
Interventions
Active Jaw Exercise with Relaxation, Active Tongue Exercise, Active Tongue Exercise + Mental Practice, Mental Practice Tongue Exercise
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
60 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

NCT03034772
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
Dorzolamide-timolol, Artificial tears
Drug · Other
Lead sponsor
Wills Eye
Other
Eligibility
45 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Royal Oak, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

NCT04115319
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856, quetiapine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Cerritos, California • Oakland, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 2:21 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 3 Interventional

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

NCT06108544
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
TAK-279, Placebo, Apremilast
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 22, 2026, 2:21 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Using Signos mHealth Platform in Adults for Weight Management

NCT06214221
View directory record Official record
Conditions
Overweight and Obesity, Metabolic Syndrome, Weight Loss
Interventions
Signos System, Standard Lifestyle Education
Device · Other
Lead sponsor
Signos Inc
Industry
Eligibility
22 Years and older
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Walnut Creek, California • North Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 1 Interventional Results available

Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects

NCT03041792
View directory record Official record
Conditions
Obesity
Interventions
Liraglutide, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Steps to Effective Problem Solving in Group Homes

NCT02855008
View directory record Official record
Conditions
Problem Behavior
Interventions
STEPS, Food for Life
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

NCT05238597
View directory record Official record
Conditions
Dry Eye Disease
Interventions
A197 Ophthalmic Solution, A197 Vehicle Control, Active Comparator
Drug
Lead sponsor
Aramis Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Garden Grove, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 1Phase 2 Interventional

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

NCT00957918
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 1 Interventional Results available

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study

NCT03340805
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 22, 2026, 2:21 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementation Strategies for Caregiver and Teacher Use of Behavioral Interventions: Aim 2

NCT07321327
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Positive Behavior Management Toolkit for Caregivers, Positive Behavioral Management Toolkit for Teachers
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 22, 2026, 2:21 AM EDT
Not listed Not applicable Interventional

Effect of Pharmacists Treating Diabetes in a FQHC

NCT03134170
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pharmacist review of therapy
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Trenton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

NCT01642550
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Artificial Tears, Tear Lipids and Tear Film Dynamics

NCT05705518
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Complete PF, Refresh Relieva PF, Refresh Optive Mega-3 PF, CVS Health Lubricant Eye Drop (PG 0.6%)
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 22, 2026, 2:21 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Birmingham, Alabama • Encinitas, California • Encino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 2:21 AM EDT
Terminated Not applicable Interventional

The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study

NCT01743547
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Yoga
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

NCT03230838
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Interventions
Ceftolozane/Tazobactam, Meropenem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
7 Days to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal

NCT02151058
View directory record Official record
Conditions
Tooth Stain
Interventions
Colgate® Regular Cavity Protection, Experimental Mouth Rinse, Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
Drug · Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years to 65 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 22, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

NCT00760578
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Miami Gardens, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 22, 2026, 2:21 AM EDT